We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well ...
Q2 FY2026 — expected 2026-07-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-067464 | EDGAR | 49K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028992 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001628280-24-007948 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001628280-23-006037 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001628280-22-003808 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001628280-21-003277 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001628280-20-002424 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001628280-19-002546 | EDGAR | — |
| 2018-02-26 | 2017-12-31 | 0001628280-18-002226 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001628280-17-002601 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269424 | EDGAR | 14K words |
| 2025-07-29 | 2025-06-30 | 0000950170-25-099610 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066886 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123242 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001628280-24-036098 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001628280-24-019974 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001628280-23-036375 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001628280-23-028549 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015692 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028164 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021044 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001628280-22-012614 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-140152 | EDGAR | 1K words |
| 2026-02-25 | 0001193125-26-068668 | EDGAR | — |
| 2026-02-24 | 0001193125-26-067476 | EDGAR | — |
| 2026-01-27 | 0001193125-26-024375 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269492 | EDGAR | — |
| 2025-07-29 | 0000950170-25-099631 | EDGAR | — |
| 2025-06-26 | 0001641172-25-016659 | EDGAR | — |
| 2025-06-17 | 0000950170-25-087369 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066947 | EDGAR | — |
| 2025-02-27 | 0000950170-25-029065 | EDGAR | — |
518 total filings indexed. 486 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001213037 |
| Ticker | CRDF |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cardiffoncology.com |
| Listed | 1997-05-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report